Pew’s specialty drugs research initiative identifies policy options that will help manage such costs and provide patients with the lifesaving treatments they need.
Research & AnalysisView All
The use of biosimilars—biological products that are highly similar to a biologic drug already approved by the Food and Drug Administration (FDA)—has the potential to reduce drug spending in Medicare Part B,1 which totaled $21.5 billion in 2014.2 However, savings to Medicare will depend on the extent to which biosimilars have lower prices than biologics—which, unlike conventional... Read More
The availability of generic drugs—which can be priced 80 percent lower than their branded equivalents—increases competition and reduces spending on pharmaceuticals. The Generic Pharmaceutical Association estimates that generic drugs generated $254 billion in savings in 2014. Read More
Pharmacists often make drugs for patients whose clinical needs cannot be met by a commercially available product, a practice known as compounding. But should pharmacists compound drugs to reduce costs for patients and the health care system? Read More